Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-05-10
2011-05-10
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C435S377000, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07939508
ABSTRACT:
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
REFERENCES:
patent: 4426330 (1984-01-01), Sears et al.
patent: 4534899 (1985-08-01), Sears et al.
patent: 4837028 (1989-06-01), Allen et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 6218108 (2001-04-01), Kool et al.
patent: 6887906 (2005-05-01), Teng et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0256069 (2005-11-01), Manoharan et al.
patent: 2008/0206198 (2008-08-01), Engelhardt et al.
patent: 2009/0149428 (2009-06-01), Smith
patent: 1 394 274 (2004-03-01), None
patent: WO 88/04924 (1988-07-01), None
patent: WO 90/04384 (1990-05-01), None
patent: WO 91/05545 (1991-05-01), None
patent: WO 94/20073 (1994-09-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 97/04787 (1997-02-01), None
patent: WO 97/13499 (1997-04-01), None
patent: WO 97/30731 (1997-08-01), None
patent: WO 02/092854 (2002-11-01), None
patent: WO 03/057847 (2003-07-01), None
patent: WO 2004/050894 (2004-06-01), None
patent: WO 2004/094636 (2004-11-01), None
patent: WO 2008/043561 (2008-04-01), None
patent: WO 2008/152131 (2008-12-01), None
Amosova et al., “Effect of the 1-(24-deoxy-b-D-ribofuranosyl)-3-nitropyrrole residue on the stability of DNA duplexes and triplexes”, Nucleic Acids Research, 1997 vol. 25 No. 10 pp. 1930-1934.
Berger et al., “Universal bases for hybridization, replication and chain termination”, Nucleic Acids Research, 2000 vol. 28 No. 15 pp. 2911-2914.
Chaudhuri et al., “Very High Affinity DNA Recognition by Bicyclic and Cross-Linked Oligonucleotides”, J. Am. Chem. Soc., 1995 vol. 117 pp. 10434-10442.
Chen et al., “Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo”, Proc. Natl. Acad. Sci., 1994 vol. 91 pp. 3054-3057.
Du Plessis et al., “The influence of particle size of liposomes on the deposition of drug into skin”, International Journal of Pharmaceutics, 1994 vol. 103 pp. 277-282.
Guckian et al., “Experimental Measurement of Aromatic Stacking Affinities in the Context of Duplex DNA”, J. Am. Chem. Soc., 1996 vol. 118 pp. 8182-8183.
Guckian et al., “Structure and Base Pairing Properties of a Replicable Nonpolar Isostere for Deoxyadenosine”, J. Org. Chem., 1998 vol. 63 pp. 9652-9656.
Ho et al., “Preparation of Microemulsions Using Polyglycerol Fatty Acid Esters as Surfactant for the Delivery of Protein Drugs”, Journal of Pharmaceutical Sciences, 1996, vol. 85 No. 2 pp. 138-143.
Loakes et al., “Stability and Structure of DNA Oligonucleotides Containing Non-specific Base Analogues”, J. Mol. Biol., 1997 vol. 270 pp. 426-435.
Loakes et al., “The applications of universal DNA base analogues”, Nucleic Acids Research, 2001 vol. 29 No. 12 pp. 2437-2447.
McMinn et al., “Efforts toward Expansion of the Genetic Alphabet; DNA Polymerase Recognition of a Highly Stable, Self-Pairing Hydrophobic Base”, J. Am. Chem. Soc., 1999 vol. 121 pp. 11585-11586.
Morales et al., “Minor Groove Interactions between Polymerase and DNA: More Essential to Replication than Watson-Crick Hydrogen Bonds?”, J. Am. Chem. Soc., 1999 vol. 121 pp. 2323-2324.
Moran et al., “Difluorotoluene, a Nonpolar Isostere for Thymine, Codes Specifically and Efficiently for Adenine in DNA Replication”, J. Am. Chem. Soc., 1997 vol. 119 pp. 2056-2057.
Moran et al., “A thymidine triphosphate shape analog lacking Watson-Crick pairing ability is replicated with high sequence selectivity”, Proc. Natl. Acad. Sci., 1997 vol. 94 pp. 10506-10511.
Oliver et al., “Effect of the Universal Base 3-Nitropyrrole on the Selectivity of Neighboring Natural Bases”, Organic Letters, 2001 vol. 3 No. 13 pp. 1977-1980.
O'Neill et al., “A Highly Effective Nonpolar Isostere at Deoxyguanosine: Synthesis, Structure, Stacking, and Base Pairing”, J. Org. Chem., 2002 vol. 67 pp. 5869-5875.
Schweitzer et al., “Aromatic Nonpolar Nucleosides as Hydrophobic Isosteres of Pyrimidine and Purine Nucleosides”, J. Org. Chem., 1994 vol. 59 pp. 7238-7242.
Shankar et al., “The Prospect of Silencing Disease Using RNA Interference”, JAMA, 2005 vol. 293 No. 11 pp. 1367-1373.
Takakura et al., “Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System”, Antisense & Nucleic Acid Drug Development, 1996 vol. 6, pp. 177-183.
Tuschl et al., “Mechanisms of gene silencing by double-stranded RNA”, Nature, 2004 vol. 431 pp. 343-349.
Vallone et al., “Melting studies of short DNA hairpins containing the universal base 5-nitroindole”, Nucleic Acids Research, 1999 vol. 27 No. 17 pp. 3589-3596.
Baker et al; “Abnormalities of Nasal Potential Difference Measurement in Liddle's Syndrome”; J. Clin. Invest. 102 (1):10-14 (1998).
Boucher; “Relationship of Airway Epithelial Ion Transport to Chronic Bronchitis”; Proc. Am. Thorac. Soc. 1:66-70 (2004).
Gibson et al; “Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis”; Am. J. Respir. Crit. care Med. 169:918-951 (2003).
Han et al; “Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease”; Zhonghua Jie He He Hu Xi Za Zhi 30(5):363-367 (May 2007)—English Abstract.
Hironaka et al; “Pulmonary Fibrosis and Lung Carcinoma: A Comparative Study of Metaplastic Epithelia in Honeycombed Arease of Usual Interstial Pneumonia With or Without Lung Carcinoma”; Pathology International 49:1060-1066 (1999).
Hirsh; “Altering Airway Surface Liquid Volume: Inhalation Therapy with Amiloride and Hyperosmotic Agents”; Advanced Drug Delivery Reviews 54:1445-1462 (2002).
Hirsh et al; “Design, Synthesis, and Structure—Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers: Drugs for Cystic Fibrosis and Chronic Bronchitis”; J. Med. Chem. 49:4098-4115 (2006).
Mall et al; “Increased Airway Epithelial Na+ Absorption Produces Cystic Fibrosis-like Lung Disease in Mice”; Nature Medicine 10(5):487-493 (2004).
MRC Working Party; “Medical Research Council Trial of Treatment of Hypertension in Older Adults: Principal Results”; BMJ 304:405-412 (1992).
Rezaiguia et al; “Acute Bacterial Pneumonia in Rats Increases Alveolar Epithelial Fluid Clearance by a Tumor Necrosis Factor-Alpha-dependent Mechanism”; J. Clin. Invest. 99(2):325-335 (1997).
Tarran et al; “Soluble Mediators, Not Cilia, Determine Airway Surface Liquid Volume in Normal and Cystic Fibrosis Superficial Airway Epithelia”; J. Gen. Physiol. 127(5):591-604 (2006).
Danahay Henry Luke
Geick Anke
Heeke Gino Van
Hickman Emma
Tan Pamela
McGarry Sean R
Novartis AG
LandOfFree
RNAi inhibition of alpha-ENaC expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi inhibition of alpha-ENaC expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi inhibition of alpha-ENaC expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2647088